Erquinghem-Lys, France

Nathalie Fournier

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Nathalie Fournier: Innovator in Monoclonal Antibodies

Introduction

Nathalie Fournier is a prominent inventor based in Erquinghem-Lys, France. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of two patents to her name, her work focuses on innovative solutions for treating various diseases.

Latest Patents

Nathalie's latest patents include the development of anti-CD303 monoclonal antibodies. This invention relates to chimeric or humanized anti-CD303 antibodies, which are crucial for the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) and inflammatory diseases, especially autoimmune diseases. Her second patent involves a cell line overexpressing the human CD303 antigen. This cell line is characterized by stable transfection with an expression vector that codes for human CD303 antigen, enabling strong expression on the cell surface.

Career Highlights

Throughout her career, Nathalie has worked with notable organizations, including Laboratoire Français Du Fractionnement Et Des Biotechnologies. Her expertise in biotechnology has allowed her to contribute to groundbreaking research and development in her field.

Collaborations

Nathalie has collaborated with esteemed colleagues such as Christophe De Romeuf and Alexandre Fontayne. These partnerships have further enhanced her research and innovation capabilities.

Conclusion

Nathalie Fournier is a trailblazer in the field of biotechnology, with her innovative patents paving the way for advancements in medical treatments. Her contributions continue to impact the scientific community positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…